6533b822fe1ef96bd127cf24
RESEARCH PRODUCT
Lunasin-induced behavioural effects in mice: Focus on the dopaminergic system
Olga MazinaAnni AllikaltAgo RinkenZane DzirkaleKaspars JekabsonsRuta MucenieceJuris RumaksVija KlusaSimons Svirskissubject
Malemedicine.medical_specialtyApomorphineDopamine AgentsMotor ActivityPharmacologyBicucullineLunasinBehavioral NeuroscienceDopamine receptor D1SeizuresDopamineInternal medicineCyclic AMPmedicineAnimalsHumansGABA-A Receptor AntagonistsAmphetamineReceptorCatalepsyReceptors Dopamine D2ChemistryReceptors Dopamine D1DopaminergicBrainMice Inbred C57BLApomorphineAmphetamineHEK293 CellsEndocrinologyDopamine receptorSoybean ProteinsKetamineExcitatory Amino Acid AntagonistsCentral Nervous System Agentsmedicine.drugdescription
The present study for the first time is devoted to identify central effects of synthetic lunasin, a 43 amino acid peptide. A markedly expressed neuroleptic/cataleptic effect was observed at low (0.1-10 nmol/mouse) centrally administered doses in male C57Bl/6 mice. Lunasin considerably reduced the amphetamine hyperlocomotion but weakly apomorphine climbing behaviour. No influence on ketamine and bicuculline effects was observed. Binding assay studies demonstrated modest affinity of lunasin for the dopamine D₁ receptor (Ki=60 ± 15 μM). In a functional assay of cAMP accumulation on live cells lunasin antagonised apomorphine effect on D₁ receptor activation (pEC₅₀=6.1 ± 0.3), but had no effect in cells expressing D₂ receptors. The obtained data suggest that lunasin's action at least in part is provided via dopaminergic D1 receptor pathways. However, other non-identified mechanisms (probably intracellular) may play an important role in lunasin's central action. Nevertheless further studies of lunasin are promising, particularly taking into account a necessity for novel type of antipsychotic drugs.
year | journal | country | edition | language |
---|---|---|---|---|
2013-11-01 | Behavioural Brain Research |